GlassScriptPhysician profile
Ilya Wolfson
NPI 1942261441
$1,939.44
in general payments reported to CMS, 2019-2025
8 companies · $986 in 2025
The $986 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $373 · 2023: $107 · 2024: $473 · 2025: $986.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,566.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $934.15 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $249.96 | 2024 | Otezla, Repatha |
| Edwards Lifesciences Corporation | $144.53 | 2025 | Sapien 3 Ultra Resilia |
| Ardelyx, INC. | $128.16 | 2025 | Ibsrela |
| Axsome Therapeutics, INC. | $125.00 | 2025 | Auvelity |
| Lilly USA, LLC | $124.98 | 2024 | Zepbound |
| Abbvie INC. | $124.97 | 2025 | |
| Novo Nordisk INC | $107.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ilya Wolfson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.